Logo image
Back
In RRP, serologic response to HPV is frequently absent and slow to develop
Journal article   Open access   Peer reviewed

In RRP, serologic response to HPV is frequently absent and slow to develop

Farrel J. Buchinsky, Nicole Ruszkay, William Valentino, Craig S. Derkay, John E. McClay, Robert W. Bastian, Charles M. Myer, Kevin W. Lollar and Dalya Guris
PloS one, v 15(3), pp e0230106-e0230106
11 Mar 2020
DOI: https://doi.org/10.1371/journal.pone.0230106
PMID: 32160246
Featured in Collection :   UN Sustainable Development Goals @ Drexel
url
https://doi.org/10.1371/journal.pone.0230106View
Published, Version of Record (VoR)CC BY V4.0,  Open

Abstract

Multidisciplinary Sciences Science & Technology Science & Technology - Other Topics
Background Recurrent respiratory papillomatosis (RRP) is characterized by repeated formation of papillomas in the respiratory tract and is caused by human papillomavirus (HPV) types 6 and 11. Women with genital HPV infection are slow to develop weak humoral immunity, but respond robustly to the HPV vaccine. We wondered if people with RRP had a similar immune response. Methods A convenience cross-sectional sample of patients with RRP were recruited into one of four groups: 1) adults and adolescents with active RRP, 2) children with active RRP, 3) RRP patients who had undergone HPV vaccination prior to enrollment and, 4) people with RRP who were in remission. Anti-HPV6 and HPV11 serology was determined by cLIA on a single blood draw. Results Of the 70 subjects enrolled, 36, 16, 8, and 10, were in groups 1, 2, 3, and 4, respectively. 47% of participants aged > 11 years and 81% aged <= 11 years possessed no antibodies against HPV6 or HPV11 (ie. double seronegative). 61% of patients in remission were double seronegative. All participants who had received HPV vaccine previously were seropositive to at least one of these low risk HPV types (ie none of them were double seronegative). Among patients who had active RRP and never had HPV vaccination (n = 52) there was an association between duration of symptoms and seropositivity. Of those who were seropositive, the geometric mean duration of symptoms was 11 years compared to 4.7 years for those who were seronegative (p = 0.001). Conclusion People with RRP are capable of developing a humoral response to HPV6 and HPV11. That response appears to be robust when initiated by the HPV vaccine, but either nonexistent or slow to develop in response to infection. Most in remission do not have demonstrable antibody levels against HPV6 or HPV11.

Metrics

13 Record Views
14 citations in Web of Science
13 citations in Scopus

Details

UN Sustainable Development Goals (SDGs)

This publication has contributed to the advancement of the following goals:

#3 Good Health and Well-Being
#5 Gender Equality

InCites Highlights

Data related to this publication, from InCites Benchmarking & Analytics tool:

Collaboration types
Domestic collaboration
Web of Science research areas
Otorhinolaryngology
Logo image